Study title: DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF NEURONTIN (GABAPENTIN) IN MIGRAINE PROPHYLAXIS ADMINISTERED IN DOSES DIVIDED THREE TIMES A DAY (TID) PROTOCOL 945-400193)
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Nervous System Diseases [C10] | |||||
Brands: Please see report, Please see report | |||||
MAH holders: Please see report, Please see report, Please see report | |||||
Assessment: | |||||
Active substance: GABAPENTIN | |||||
ATC code: | |||||
Document link: | |||||
Document date: | |||||
Study number: 0945-400-200* | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | - |